G protein subunit alpha 12Genealiases: HG1M1 · NNX3 · RMP · gep
Q-omics provides the consensus-scored GNA12 profile across patient tissues and cancer cell-line models. GNA12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GNA12 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, GNA12 RNA expression shows 19,847 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where GNA12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNA12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNA12 survival associations across molecular data types. GNA12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNA12 RNA expression–survival associations across cancer types. High GNA12 expression shows unfavorable associations in MESO, BLCA, LIHC, CESC, ACC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GNA12 RNA expression.
This table summarizes GNA12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GNA12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNA12 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, LUAD and COAD. The HNSC box plot shows higher GNA12 RNA expression in tumor versus normal tissue (log2 FC = +2.520, t-test p < 0.001).
This table shows molecular features associated with GNA12 in patient tissues and cancer cell lines. In patient samples, GNA12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNA12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
